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Neural stem cells (NSCs) have been considered as potential therapy in Alzheimer's disease (AD) but their use is hampered by the
poor survival of grafted cells. Supply of neurotrophic factors to the grafted cells has been proposed as a way to augment
survival of the stem cells. In this context, we investigated the utility of Cerebrolysin (CBL), a peptidergic mixture with
neurotrophic-like properties, as an adjunct to stem cell therapy in an APP transgenic (tg) model of AD. We grafted murine NSCs
into the hippocampus of non-tg and APP tg that were treated systemically with CBL and analyzed after 1, 3, 6 and 9 months
post grafting. Compared to vehicle-treated non-tg mice, in the vehicle-treated APP tg mice there was considerable reduction
in the survival of the grafted NSCs. Whereas, CBL treatment enhanced the survival of NSCs in both non-tg and APP tg with the
majority of the surviving NSCs remaining as neuroblasts. The NSCs of the CBL treated mice displayed reduced numbers of
caspase-3 and TUNEL positive cells and increased brain derived neurotrophic factor (BDNF) and furin immunoreactivity. These
results suggest that CBL might protect grafted NSCs and as such be a potential adjuvant therapy when combined with grafting.
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The neurogenerative process in patients with Alzheimer's
disease (AD) is characterized by synaptic loss (Overk and
Masliah, 2014) and loss of cholinergic, glutaminergic and
GABA-ergic neurons (DeKosky et al., 1996; Masliah, 1995,
2001; Masliah et al., 2006; Scheff et al., 1990; Terry et al.,is an open access article under the CC BY-NC-ND license
55CBL effects grafted stem cells in APP mice1991; Trojanowski et al., 1995). In addition, more recent
studies suggest that alterations in adult neurogenesis in
the hippocampus might also contribute to the neurodegener-
ative process in AD (Dong et al., 2004). There is some
controversy over whether neurogenesis is increased (Jin
et al., 2004) or decreased (Boekhoorn et al., 2006; Li et al.,
2008) in AD. Recent studies suggest that apparent increases in
neurogenesis in AD patients may be related to glial and
vasculature-associated changes (Boekhoorn et al., 2006).
Studies in a number of animal models of Familial AD have
shown that neurogenesis is reduced (Dong et al., 2004; Donovan
et al., 2006; Haughey et al., 2002; Rockenstein et al., 2007).
The mechanisms of neurodegeneration in AD are not
completely clear, however progressive accumulation of amy-
loid beta (Aβ) with the formation of oligomers appears to
trigger a complex cascade of events that includes activation of
several kinases including glycogen synthetase kinase (GSK3β)
and cyclin dependent kinase-5 (CDK5) (Crews and Masliah,
2010; Engmann and Giese, 2009; Shukla et al., 2012) leading to
aberrant post-transcriptional modification of the microtubule
binding protein—Tau (Gong and Iqbal, 2008). Moreover, other
studies suggest that deficient transport or expression of
neurotrophic factors (NTF) (e.g., nerve growth factor [NGF],
brain derived neurotrophic factor [BDNF]) and their receptors
might be involved (Peng et al., 2005; Schindowski et al., 2008;
Scott et al., 1995). For this reason, experimental therapies for
AD involve reducing the Aβ load, blocking kinases such as
GSK3β and CDK5, reducing Tau and replacement therapies
with NTFs (Blurton-Jones et al., 2009; Nagahara et al., 2009;
Tuszynski, 2007; Tuszynski et al., 2005).
However, given the advanced clinical stage at which
several patients with AD present, alternative therapies are
under consideration including replacement therapy with
neuronal stem cell grafts. For example, previous studies
have shown that neural stem cells (NSC) transferred into the
hippocampus of AD transgenic (tg) models improve cognition
via BDNF (Nagahara et al., 2009, 2013) and reduce Tau and
reelin accumulation in aged Ts65DNmodel of Down's syndrome
(Kern et al., 2011). Moreover, transplantation of NSC derived
from induced pluripotent stem cells (iPSC) restore memory in
amyloid precursor protein (APP) tg (Fujiwara et al., 2013) and
APP/Presenilin-1 (PS1) mice (Zhang et al., 2014a) supporting
the notion that treatment with NSCs might be of useful in AD
patients. However, a potential problem is the reduced
viability of the transplanted cells given the noxious micro-
environment in the brain of patients with AD. For example, we
have recently shown that under baseline conditions NSC
display reduced viability when transplanted into the brains
of APPmice, howeverwhen these cells aremodified to express
the Aβ degrading enzyme, neprilysin, the stem cells are more
prone to survive (Blurton-Jones et al., 2014). Therefore,
adjuvant therapies that enhance survival of grafted stem cells
might be important.
Among them, we have considered the potential of combin-
ing stem cells with Cerebrolysin™ (CBL) a peptide mixture with
neurotrophic-like properties that improves cognition in pa-
tients with mild to moderate AD (Alvarez et al., 2006, 2011;
Plosker and Gauthier, 2009, 2010; Ruther et al., 1994, 2000).
CBL has been shown to be protective in experimental models of
excitotoxicity (Veinbergs et al., 2000) and stroke (Onishchenko
et al., 2008; Ren et al., 2007; Zhang et al., 2010). In addition,
CBL is neurotrophic in APP tg models of AD by promotingsynaptic formation and neurogenesis (Blanchard et al.,
2010a,b; Chohan et al., 2011; Rockenstein et al., 2002, 2003,
2005, 2007). The protective effects of CBL in AD-like models
involve different mechanisms including regulation of GSK3β
and CDK5 signaling, control of APP metabolism and anti-
apoptotic effects mediated by expression of endogenous
neurotrophic factors (Ubhi et al., 2013). In this context, the
main objective of this study was to investigate whether CBL is
capable of enhancing the survival of transplanted NSCs. We
found NSC survival progressively declined with age in APP tg
mice when compared to controls and that adjuvant therapy
with CBL enhanced survival of the BrdU tagged grafted NSC.
This study supports the notion that CBL might be a potentially
useful adjuvant therapy in combination with NSCs.Materials and methods
Preparation and CBL testing in mouse cortical
neural stem cells
Briefly, as previously described (Crews et al., 2011; Desplats
et al., 2012), mouse cortical NSCs were obtained from
Millipore. The NSCs were grown on F12/DMEM basal media
supplemented with B27 and were kept in proliferative status
without induction of neuronal differentiation. Cells were
labeled 48 h prior to grafting into the mouse by infection
with lentiviral constructs containing the GFP coding se-
quence at a MOI = 50. Additional pulse labeling with BrdU
was carried out 24 h prior to grafting. For in vitro
experiments, NSCs were treated with vehicle alone or CBL
(5%) and grown in 35 mm dishes and in 6 well plates with a
coverslip in the bottom for subsequent ELISA and immuno-
cytochemical studies respectively.Generation of APP Tg Mice, grafting and
Cerebrolysin treatment
For these experiments, hAPP tg mice expressing mutated
(Swedish K670M/N671L, London V717I) human(h) APP751 under
the control of themouse (m) Thy-1 promoter (mThy1-hAPP751)
(line 41) (Rockenstein et al., 2001) were used. Thesemice have
been extensively characterized (Crews et al., 2010, 2011;
Havas et al., 2011; Rockenstein et al., 2011; Spencer et al.,
2008) and we have previously shown that these mice display
loss of synaptic contacts, defects in neurogenesis, high levels of
Aβ1–42 production, early amyloid deposition and behavioral
deficits (Rockenstein et al., 2003, 2007). Genomic DNA was
extracted from tail biopsies and analyzed by PCR amplification,
as described previously (Rockenstein et al., 1995). Transgenic
lines were maintained by crossing heterozygous tg mice with
non-transgenic (non tg) C57BL/6 × DBA/2 F1 breeders. All mice
were heterozygous with respect to the transgene.
A total of 128mice (3 month old) were included in this study
(n = 64 non-tg and n = 64 APP tg mice) that were divided into
groups of n = 32 corresponding to the post graft time points at
which they were analyzed (1, 3, 6 and 9 months). All animals
received bilateral stereotaxical injections of the green fluores-
cent protein (GFP) and BrdU tagged NSC suspension containing
5 × 104 cells/μl. Each of the groups (4 groups × n = 32 per time
point) included n = 16 non-tg (n = 8 vehicle and n = 8 CBL) and
56 E. Rockenstein et al.n = 16 APP tg (n = 8 vehicle and n = 8 CBL) mice. CBL was
provided by EVER Pharma in pre-prepared ampoules, each
milliliter of CBL contains 215.2 mg of the active CBL concen-
trate in an aqueous solution (EBEWENeuroPharmaGmbH, 2009).
Mass spectrometry analysis of CBL has shown that it is
comprised of amino acids (80%) and small (b10 Da) peptides
(20%) and previous work had shown that this small peptides
mimic the effect of neurotrophic factors including ciliary
neurotrophic factor (CNTF), fibroblast growth factor 2 (FGF2)
and insulin-like growth factor (IGF) (Chen et al., 2007). Mice
were injected daily for the duration of the experiment with
saline alone or CBL (i.p., 5 ml/kg, CBL Batch #92382008) for a
total of 1, 3, 6 or 9 months. By the end of the experiment for
each corresponding group mice were 4, 6, 9 and 12 months old.
All experiments described were approved by the animal
subjects committee at the University of California at San Diego
(UCSD) and were performed according to NIH guidelines for
animal use.
Tissue processing
In accordance with NIH guidelines for the humane treatment
of animals, mice were anesthetized with chloral hydrate and
flush-perfused transcardially with 0.9% saline. Brains were
removed and divided sagitally. The left hemibrain was
post-fixed in phosphate-buffered 4% paraformaldehyde
(pH 7.4) at 4 °C for 48 h and sectioned at 40 μm with a
Vibratome 2000 (Leica, Germany), while the right hemibrain
was snap frozen and stored at −70 °C.
Immunohistochemical analysis
Briefly, as previously described (Blurton-Jones et al., 2014;
Rockenstein et al., 2007), blind-coded 40 μm thick vibratome
sections were immunolabeled with mouse monoclonal anti-
bodies against BrdU (1:500, Millipore), PCNA (1:500, Millipore),
GFAP (1:500, Milllipore), NeuN (1:500, Millipore), doublecortin
(DCX) (1:500, Millipore), Ki-67 (1:100, Santa Cruz), activated
caspase-3 (1:1000, Cell Signal), BDNF (1:250, Abcam), NT4
(1:100, Pierce) and furin (1:100, Pierce) followed by horse anti
mouse biotinylated secondary antibody and developed with
diaminobenzidine and imaged with an Olympus OX54 digital
photomicroscope. An additional series of sections were
incubated with antibodies against the dendritic marker MAP2
(1:500, Milllipore) and Aβ (1:500, 82E1, IBL). After overnight
incubation with the primary antibodies, sections were incu-
bated with FITC-conjugated horse anti-mouse IgG secondary
antibody (1:75, Vector Laboratories, Burlingame, CA), trans-
ferred to SuperFrost slides (Fisher Scientific, Tustin, CA) and
mounted under glass coverslips with anti-fading media
(Vector). Moreover, double immunolabeling experiments
were performed with the following combinations of antibod-
ies: 1) anti-BrdU and anti-GFP; 2) anti-NeuN and anti-GFP;
3) anti-GFAP and anti-GFP; 4) anti-olig-2 and anti-GFP;
5) anti-BDNF and anti-GFP and 6) anti-Furin and anti-GFP.
The BrdU, NeuN, GFAP, olig-2, BDNF and furin were detected
with Tyramide Red (NEN) while the GFP was detected via
amplification with FITC (green channel). All sections were
processed under the same standardized conditions. The
immunolabeled sections were imaged with the laser-scanning
confocal microscope (LSCM, MRC1024, BioRad, Hercules, CA)and analyzed as previously described (Rockenstein et al.,
2003). Briefly, for each section a total of 8 images at 630×
were analyzed. For each image a thresholdwas set utilizing the
Image Quant system, the threshold was set within a dynamic
range that was consistent for all cases. The levels of pixel
intensity or optical density for the area were ascertained with
the measure tool of the system. An adjacent un-stained area
was used as background to correct against. Area of images
analyzed was on average 1024 by 1024 pixels. This area
included on average at least 4–5 neurons that were analyzed.
The average integrated pixels of optical density for all neurons
within that area were estimated and then averaged by the 16
images captured. The average was corrected to the back-
ground and expressed as an overall mean by mouse per group.
To confirm the specificity of primary antibodies, control
experiments were performed where sections were incubated
overnight in the absence of primary antibody (deleted) or with
preimmune serum or with primary antibody alone.
Unbiased stereology
Stereological methods were used to estimate the number of
BrdU immunoreactive cells utilizing an optical fractionator
unbiased sampling design (Rockenstein et al., 2007). A total of
4 alternating sections separated by approximately 250 μm
containing the hippocampus were outlined using a 4×
objective attached to an Olympus BX51 microscope. Anatom-
ical nomenclature was based on Paxinos and Franklin (2001). A
systematic sampling of the outlined areas was made from a
random starting point using StereoInvestigator 8.21.1 soft-
ware (Micro-BrightField, Cochester, VT). Counts were taken at
predetermined intervals (x = 152, y = 152), and a counting
frame (70 × 70 μm = 4900 μm2) was superimposed on the live
image of the tissue sections. Sections were analyzed using a
60× 1.4 PlanApo oil-immersion objective with a 1.4 numerical
aperture. Section thickness was determined by focusing on the
top of the section, zeroing the z-axis and focusing on the
bottom of the section. Average section thickness was 18 μm.
The dissector height was set at 12 μm. This allowed for a 2-μm
top guard zone and at least a 2-μm bottom guard zone. The
forbidden zones were never included in the cell counting.
Immunoreactive neurons were only counted if the first
recognizable profile came into focus within the counting
frame. This method allowed for a uniform, systematic, and
random design. Differences in stereologic counts were
evaluated using the Mann–Whitney test for median differ-
ences (GraphPad Prism 4.0c for Macintosh, San Diego, CA).
The level of statistical significance was set at p-value b 0.05.
Determination of NTF protein content by ELISA
As previously described (Ubhi et al., 2013), levels of Furin and
BDNF were determined in whole brain homogenates by ELISA
according to the supplier's protocol (Promega, Madison, WI).
The samples were sonicated in a homogenization buffer
(20 mM Tris, pH 8, 137 mM NaCl, 1% Nonidet P-40, 1.7 μg/ml
phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 1 μg/ml
leupeptin and 0.5 mM sodium vanadate) at a tissue concen-
tration of 30 μl/mg. An additional control ELISA was per-
formed on whole brain homogenates from non tg mice that
had been treated with an amino acid control for CBL.
57CBL effects grafted stem cells in APP miceStatistical analysis
Statistical analysis was performed with the Prism Graph path
software package (La Jolla, CA). All results are expressed as
mean plus minus SEM. Differences among multiple groups
were assessed by one-way ANOVA with post-hoc Dunnett's
when comparing to the control group, comparisons among
the treatment groups was performed with the Tukey posthoc
test. Comparisons between 2 groups were assessed using the
two-tailed unpaired Student's t-test.Results
The reduced survival of grafted NSCs in the brains of
APP tg mice is improved by Cerebrolysin treatment
To investigate the survival of grafted cells in APP tg mice,
cortical derived mouse NSCs labeled with BrdU and GFP were
injected into the hippocampus and mice were analyzed 1, 3, 6
and 9 m post transplantation. Immunocytochemical analysis
with an antibody against BrdU showed that the transplanted
cells distributed mostly around the CA1 region, the dentate
gyrus and the sub-granular zone of the hippocampus (Figs. 1A–
C). After 1 month, in the vehicle-treated non-tg mice an
average of 13,100 per unit area were found, which was
equivalent to approximately to 13.5% of the grafted cells
(Figs. 1A, D). After 3 months there was a decline to 5.8% that
was stabilized after 6 and 9 months post transplant (6.5%)
(Figs. 1B, D). When compared to the non-tg vehicle control
group, in the APP tg mice there was a significant reduction in
the survival of the grafted cells 1 m post-graft (5100 cells or
5.4%) (Figs. 1B, D). At the later time points only few grafted
cells (less than the equivalent to 1%) were found in the vehicle
APP tg group (Figs. 1C, D). In the non-tg mice, the numbers of
BrdU positive NSCs were similar in the vehicle and CBL treated
mice, however after 3, 6 and 9 months survival was higher
(14%) in the CBL treated mice compared to vehicle (5.8%) (Fig.
1D). After 1 month in the CBL treated APP tg mice the
numbers of BrdU positive NSCs (18,900 or 24%) were above the
non-tg groups and the vehicle treated APP mice (Figs. 1A, D).
After 3, 6 and 9 months of the transplant the numbers of
surviving NSCs were comparable to the non-tg CBL group
(12.1%) and above the vehicle-treated APP tg (less than 1%)
(Figs. 1B–D). To further corroborate that the BrdU detected
cells were the grafted cells, double labeling experiments were
performed with antibodies against BrdU and GFP. By confocal
microscopy it was observed that the great majority of the GFP
positive cells also displayed BrdU reactivity (Figs. 1E, F).
These results support the notion that grafted NSC display poor
survival in the brains of APP tg mice and that adjuvant
treatment with CBL reverts this effect.
Effects of Cerebrolysin and NSC grafting on AD-like
neuropathology and endogenous neurogenesis in
APP tg mice
To confirm the presence of AD-like neuropathology in the
brains of APP tg mice and to evaluate the impact of the
combined effects of NSC grafting and CBL treatment sections
were immunolabeled with antibodies against Aβ and GFAP.As expected compared to the non-tg group the vehicle-
treated APP tg mice displayed extensive Aβ deposition in
the neocortex and hippocampus that increased over time
(Figs. 2A–C upper panels, D). In contrast, the CBL treated
APP tg mice displayed a reduced amyloid deposition that
was more prominent 6 and 9 months post-graft and CBL
treatment (Figs. 2C upper panels, D). With the antibody
against GFAP, in both groups of APP tg mice there was
astrogliosis more prominent in the hippocampus than in the
neocortex (Figs. 2A–C lower panels). Besides the expected
astrogliosis along the injection site no prominent glial
reaction was observed as result of the placement of the
NSC graft (Figs. 2A–C lower panels). Next we analyzed the
effects on neurodegeneration, as we have previously shown
that APP tg mice display age related synapto-dendritic loss
in the dentate gyrus of the hippocampus (Rockenstein et al.,
2002). For this purpose sections were immunolabeled with
an antibody against MAP2 and analyzed by confocal
microscopy (Fig. 3A). Analysis at 1 month after grafting
showed that non-tg and APP tg mice displayed comparable
levels of MAP2 immunoreactivity in the molecular layer of
the dentate gyrus, although compared to the vehicle, the
CBL treated group had slightly higher levels of MAP2
(Figs. 3A, B). However, 3, 6 and 9 m post-grafting the
vehicle-treated APP tg mice displayed a significant reduc-
tion in the % area of the neuropil covered by MAP2 immuno-
reactive dendrites (Figs. 3A, B). Compared to vehicle group,
grafted APP tg mice displayed levels of MAP2 comparable to
the non-tg mice (Fig. 3B).
We have previously shown that in addition to the synapto-
dendritic damage, APP tg mice display reduced neurogenesis
in the hippocampus (Rockenstein et al., 2007). To evaluate
the combined effects of NSC grafting and CBL treatment on
endogenous neurogenesis, sections were immunostained
with an antibody against double-cortin DCX (Fig. 3C).
Analysis at 1 month after grafting showed that compared
to vehicle treated non-tg, the APP tg mice displayed a 47%
reduction in the number of DCX positive neuroblasts in the
subgranular zone of the hippocampus (Figs. 3C, D), in
contrast grafted APP tg mice treated with CBL displayed
DCX levels comparable to the un-treated non-tg mice
(Fig. 3D). After 3, 6 and 9 m post-grafting the vehicle
treated APP tg mice displayed further reduction in the
numbers of DCX immunoreactive cells (Figs. 3C, D). A similar
trend was observed 3 months after grafting in the non-tg
mice and in the CBL treated APP tg (Figs. 3C, D). However,
at 6 and 9 months numbers of DCX immunoreactive cells
leveled (Fig. 3C). Taken together, these studies suggest that
the combined effects of enhanced survival of NSC with CBL
reduce neurodegeneration in the hippocampus of APP tg
mice by ameliorating the degeneration of granular cells and
endogenous neuroblasts in the hippocampal dentate gyrus.Cerebrolysin treatment promotes survival of grafted
NSC with no evidence of tumoral proliferation
Given that a subpopulation of grafted NSCs distributes in the
dentate gyrus and that there is reduced neurodegeneration
and increased endogenous neurogenesis in the granular
zone, it is possible that CBL might promote differentiation
and integration of grafted NSCs into the hippocampus. To
Figure 1 Immunocytochemical analysis of BrdU labeled grafted NSCs in CBL-treated hAPP tg mice. Cortical NSCs labeled with BrdU
were transplanted into the hippocampus of non-tg and APP tg mice (3 m/o) treated with vehicle or CBL and immunocytochemical
analysis was performed after with vibratome sections 1, 3, 6 and 9 m post graft. (A, B, C) Upper panel representative images at low
power (20×) 1, 3 and 9 months post graft respectively. Lower panel is higher magnification (400×) of the area in the upper panel
marked by an open square. Arrows indicate BrdU labeled grafted NSCs distributed along the dentate granular cell layer (DGL).
(D) Computer aided image analysis of the numbers of BrdU positive cells in the hippocampus 1, 3, 6 and 9 m post graft. (E, F) Double
labeling and confocal microscopy studies for BrdU (red) and GFP (green) in the hippocampus of grafted animals showing high levels of
co-localization between the two markers (Bar = 10 μm). All results are presented as mean ± SEM, each of the four groups includes
n = 32 per time point (n = 16 non-tg [n = 8 vehicle and n = 8 CBL] and n = 16 APP tg [n = 8 vehicle and n = 8 CBL] mice). * = p b 0.05
between vehicle-treated non-tg and APP tg by one-way ANOVA and post Dunnet's. ** = p b 0.05 between vehicle-treated and
CBL-treated groups by one-way ANOVA and post hoc Tukey–Kramer. Bar = 250 μm for low power panel and 50 μm for high power
panel.
58 E. Rockenstein et al.investigate this possibility sections were double labeled with
antibodies against a mature neuronal marker (NeuN, red)
and GFP (to enhance the visualization of the tagged grafted
NSCs). Consistent with the BrdU immunocytochemistry
studies (Figs. 1A–C), GFP positive cells were identified in
the sub-granular zone of the dentate gyrus and in between
granular cells (Fig. 4A). At 1 m post grafting, compared to
vehicle treated non-tg mice, the vehicle treated APP tg mice
displayed a 82% reduction in the numbers of surviving GFP
positive NSCs (Figs. 4A, B). In contrast, CBL treatment
resulted in an increased number of GFP positive NSCs in the
dentate gyrus of non-tg and APP tg mice above the baseline
of the controls (Figs. 4A, B). At 3, 6 and 9 months
post-grafting there was a mild decline in GFP positive cells
in the vehicle treated non-tg mice (Fig. 4A), while in thevehicle treated APP tg mice the numbers remained very low
(Figs. 4A, B). Whereas the CBL treated non-tg and APP tg
mice continued to show the presence of GFP positive NSCs
above baseline controls (Figs. 4A, B). In all four experimen-
tal groups, closer analysis of the immunolabeled sections
showed that none of the GFP positive cells were NeuN
positive, neither the GFP positive NSCs displayed the
presence of neuritic extensions or integration into the
dentate gyrus (Fig. 4A arrowheads). Additional double
labeling analysis was performed with antibodies against the
astroglial marker GFAP (red channel) and GFP (green
channel) (Fig. 4C). About 2% of the GFP positive NSCs
displayed GFAP immunoreactivity and a glial like morphology
(Fig. 4C). Compared to non-tg mice in the APP tg mice at
3 months post grafting there was an increase in the % of cells
Figure 2 Neuropathological analysis of AD-like pathology in NSC grafted and CBL-treated APP tg mice. Vibratome sections from
non-tg and APP tg mice treated with vehicle or CBL and grafted with NSCs were immunolabeled with antibodies against Aβ (FITC,
imaged with the laser scanning confocal microscope) and GFAP (DAB, imaged by digital video microscopy). (A, B, C) Upper panel
representative images at low power (20×) at 1, 3 and 9 months post graft respectively. Middle panel is higher magnification (400×) of
the hippocampus dentate gyrus. Arrows indicate site of the injection and tract. Lower panel representative images at low power
(20×) of the neocortex and hippocampus with an antibody against GFAP. (D) Computer aided image analysis of the Aβ amyloid load in
the hippocampus 1, 3, 6 and 9 m post graft. All results are presented as mean ± SEM, each of the four groups includes n = 32 per time
point (n = 16 non-tg [n = 8 vehicle and n = 8 CBL] and n = 16 APP tg [n = 8 vehicle and n = 8 CBL] mice). ** = p b 0.05 between
vehicle-treated and CBL-treated APP tg mice by one-way ANOVA and post hoc Tukey–Kramer. Bar = 250 μm for low power panel and
50 μm for high power panel.
59CBL effects grafted stem cells in APP micedisplayed GFP and GFAP immunostaining (Figs. 4C, D). No
significant effects were detected following CBL treatment
(Fig. 4D).
These findings support the notion that CBL might act by
enhancing the survival (or proliferation) of grafted NSCs rather
than by promoting differentiation. Based on the initial studies
showing that starting at 3 months post grafting CBL supports
the viability of NSC (Fig. 1B) and to further evaluate the
effects of CBL on NSC survival and proliferation sections of
mice at the 9 month post-graft were immunolabeled with
antibodies against activated caspase-3 and PCNA and stained
with a modified version of the TUNEL technique (Fig. 5A).
Compared to vehicle treated non-tg mice, the CBL treated
mice showed reduced active capase-3 and TUNEL positive
NSCs (Fig. 5B). In contrast, vehicle treated APP tg mice
displayed higher numbers of active capase-3 and TUNEL
positive NSCs (Figs. 5B, C), this effect was reversed by CBL
treatment (Figs. 5B, C). Occasional PCNA immunoreactivitywas detected in the grafted NSCs; no significant differences
were detected among the four groups (Fig. 5D). Likewise,
analysis with an antibody against the proliferation marker-
Ki-67, at low power no evidence of tumoral proliferation was
noted (Fig. 6A), at higher magnification occasional Ki-67
positive cells were noted in the hippocampus (Fig. 6B arrows),
treatment with CBL did not reveal an increase in proliferation
of NPCs in the grafted area at any of the time points including
9 months post transplantation (Figs. 6B and C). Together
these results support the possibility that CBL might enhance
the survival of grafted NSCs.Adjuvant therapy with Cerebrolysin results in
increased BDNF and furin levels in grafted NSCs
Since it has been previously shown that CBL increases the
conversion of pro-NGF to mature NGF via furin (Ubhi et al.,
Figure 3 Immunohistochemical analysis of levels of MAP2 and endogenous DCX immunoreactivity in the hippocampus of NSC
grafted and CBL-treated APP tg mice. Vibratome sections from non-tg and APP tg mice treated with vehicle or CBL and grafted with
NSCs were immunolabeled with an antibody against MAP2 (FITC, imaged with the laser scanning confocal microscope) and
doublecortin (DCX) and imaged with the digital video microscope. (A) Representative images at 1, 3 and 9 months post graft
respectively of the dendritic arbor (inner molecular layer) of the dentate granular cells. (B) Computer aided image analysis of the %
area of the neuropil occupied by MAP2 dendrites at 1, 3, 6 and 9 m post graft. (C) Representative images at 1, 3 and 9 months post
graft respectively of the sub-granular zone and dentate gyrus. (D) Computer aided stereological analysis of the estimated DCX+ cell
counts at 1, 3, 6 and 9 m post graft. All results are presented as mean ± SEM, each of the four groups includes n = 32 per time point
(n = 16 non-tg [n = 8 vehicle and n = 8 CBL] and n = 16 APP tg [n = 8 vehicle and n = 8 CBL] mice). * = p b 0.05 between
vehicle-treated non-tg mice and vehicle treated APP tg mice by one-way ANOVA and post hoc Dunnet's. ** = p b 0.05 between
vehicle-treated and CBL-treated APP tg mice by one-way ANOVA and post hoc Tukey–Kramer. Bar = 50 μm.
60 E. Rockenstein et al.2013) and that NSCs can protect adjacent cells via
neurotrophic factor production (Blurton-Jones et al.,
2009), we analyzed the levels of BDNF, NT4 and furin by
immunocytochemistry (Fig. 5E). This study showed that both
in non-tg and tg mice levels of BDNF and furin immunostain-
ing were increased in the NSCs of CBL treated mice (Figs. 5E,
F, H). No differences were detected for NT4 (Figs. 5E, G). To
further confirm that the grafted NSCs were producing BDNF
and furin double labeling with GFP was performed (Figs. 5I,
K). These studies showed that in the saline treated animals
an average of 4% (Figs. 5I, J) and 10% (Figs. 5K, L) of the GFP
positive NSCs displayed BDNF or furin immunoreactivity
respectively. Treatment with CBL resulted in an increase in
the proportion of GFP positive cells displaying BDNF (Figs. 5I,
J) or furin immunolabeling (Figs. 5K, L). Further analysis of
CBL effects on NSCs was performed in vitro at 0, 4 and 8 DIV.This study showed that CBL increased BrdU levels (Figs. 7A,
B) and decreased TUNEL positive cells at 4 and 8 DIV
(Figs. 7C, D). At 4 and 8 DIV the % of MAP2 positive cells
increased but no differences were detected between the
vehicle and CBL groups (Figs. 7E, F). Moreover, analysis of
the levels of BDNF (Fig. 7G) and furin (Fig. 7H) by ELISA with
cell lysates at 8 DIV showed a 20–30% increase following CBL
treatment (Figs. 7G, H). In conclusion, CBL might enhance
the survival of grafted NSC via furin mediated BDNF
processing.Discussion
The present study showed that CBL treatment enhanced the
survival of grafted NSCs in APP tg mice. In contrast, in the
Figure 4 Laser scanning confocal microscopic analysis of neuronal and glial maturation of the grafted NSCs in the hippocampus of
CBL-treated APP tg mice. Vibratome sections from non-tg and APP tg mice treated with vehicle or CBL and grafted with NSCs (GFP
tagged) were double-immunolabeled with antibodies against NeuN (red) or GFAP (red) and GFP (green) and imaged with the laser
scanning confocal microscope. (A) Representative images at 1, 3 and 9 months post graft respectively of the hippocampal dentate
gyrus. Images illustrate granular cells (red) and the grafted NSCs (green, arrowheads) that migrated along the sub-granular zone.
(B) Computer aided image analysis of the estimated GFP+ cells at 1, 3, 6 and 9 m post graft. (C) Representative images at 1, 3 and
9 months post graft respectively of the hippocampal dentate gyrus. Images illustrate astroglial cells in the dentate gyrus (red) and the
grafted NSCs (green) along the sub-granular zone. (D) Computer aided image analysis of the % of co-localization between GFP+ and
GFAP cells at 1, 3, 6 and 9 m post graft. (E) Representative images at 1, 3 and 9 months post graft respectively of the hippocampal
dentate gyrus. Images illustrate oligodendrocytes (olig-2) in the dentate gyrus (red) and the grafted NSCs (green) along the
sub-granular zone. (F) Computer aided image analysis of the % of co-localization between GFP+ and olig-2 cells at 1, 3, 6 and 9 m post
graft. All results are presented as mean ± SEM, each of the four groups includes n = 32 per time point (n = 16 non-tg [n = 8 vehicle
and n = 8 CBL] and n = 16 APP tg [n = 8 vehicle and n = 8 CBL] mice). * = p b 0.05 between vehicle-treated non-tg mice and vehicle
treated APP tg mice by one-way ANOVA and post hoc Dunnet's. Bar = 25 μm.
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Figure 5 Immunocytochemical and double labeling analysis of markers of cell survival and neurotrophic factors in the grafted NSCs in
CBL-treated APP tg mice. Vibratome sections from non-tg and APP tg mice treated with vehicle or CBL and grafted with NSCs were
immunolabeled with antibodies against markers of cell death and survival (act casp3, TUNEL and PCNA) and neurotrophic factors (BDNF,
NT4 and furin) and imaged with the digital video microscope. (A) Representative images of vehicle and CBL treated APP tg mice at
9 months post graft respectively of the sub-granular zone and dentate gyrus. (B, C, D) Computer aided image analysis of the estimated
active caspase 3, TUNEL and PCNA positive cells at 9 months post graft,respectively. (E) Representative images of vehicle and CBL
treated APP tg mice at 9 months post graft respectively of the sub-granular zone and dentate gyrus. (F, G, H) Computer aided image
analysis of the estimated BDNF, NT4 and Furin positive cells at 9 months post graft respectively. (I) Vibratome sections from non-tg and
APP tg mice treated with vehicle or CBL and grafted with NSCs (GFP tagged) were double-immunolabeled with antibodies against BDNF or
furin (red) and GFP (green) and imaged with the laser scanning confocal microscope. Representative split images for BDNF (red) and GFP
(green) at 9 months post graft of NSC graft in the hippocampal dentate gyrus of vehicle and CBL treated APP tg mice. Images illustrate
BDNF co-localization with the GFP tag in the NSCs (arrowhead). (J) Computer aided image analysis of the % of GFP cells that co-localized
with BDNF at 9 m post graft. (K) Representative split images for furin (red) and GFP (green) at 9 months post graft of NSCs in the
hippocampal dentate gyrus of vehicle and CBL treated APP tg mice. Images illustrate furin co-localization with the GFP tag in the NSCs
(arrowhead). (L) Computer aided image analysis of the % of GFP cells that co-localized with furin at 9 m post graft. All results are
presented as mean ± SEM, n = 16 non-tg (n = 8 vehicle and n = 8 CBL) and n = 16 APP tg (n = 8 vehicle and n = 8 CBL) mice. * = p b 0.05
between vehicle-treated non-tg mice and CBL treated non-tg mice by one-way ANOVA and post hoc Dunnet's. ** = p b 0.05 between
vehicle-treated and CBL-treated APP tg mice by one-way ANOVA and post hoc Tukey–Kramer. Bar = 10 μm.
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Figure 6 Immunocytochemical analysis of the proliferation marker Ki-67 in the grafted NSCs in CBL-treated APP tg mice.
Vibratome sections from non-tg and APP tg mice treated with vehicle or CBL and grafted with NSCs were immunolabeled with an
antibody against Ki-67 and imaged with the digital video microscope. (A) Representative low power images (20×) of vehicle and CBL
treated mice at 1,3 and 9 months post graft respectively of the neocortex and hippocampus, dotted open circle represent are of
graft, bar = 250 μm. (B) Representative higher power images (630×) of Ki-67 positive cells (arrows) for the vehicle and CBL treated
mice at 1,3 and 9 months post graft respectively of the hippocampus of the corresponding site of the graft (dotted open circle in A),
bar = 25 μm. (C) Computer-aided image analysis of the numbers of Ki-67 positive cells in the hippocampus of the non-tg and APP tg
mice.
63CBL effects grafted stem cells in APP micevehicle-treated group there was decreased survival of
transplanted neuroblasts that was worse in the APP tg mice.
This is consistent with studies showing that the toxic
microenvironment in the brain of APP tg mice might compro-
mise the survival of both endogenous and transplanted NSCs.
For example, a recent study showed that oligomerized Aβ42
promoted the expression of senescence-associated biomarkers
p16 and senescence-associated β-galactosidase (SA-β-gal) in
adult mouse hippocampal NSCs, and reduced the proliferation
and differentiation of these cells in vitro and in APP/PS1 tg
mice (He et al., 2013). Moreover, we have observed that
extracellular Aβ triggers apoptosis of transplanted NSCs and
that genetically modified NSCs expressing neprilysin reduces
amyloid load in APP tg mice and enhances the survival of NSCs
and adjacent host neurons (Blurton-Jones et al., 2014),
supporting the view of beneficial effects of combined therapy
with stem cells.
Previous studies have shown that transfer of rodent NSC
into the hippocampus of APP/PS1 tg mice reduces behavioral
deficits without changing amyloid β burden (Zhang et al.,
2014a) and transplantation of NSCs derived from human iPSC
reduce memory deficits in APP mice (Fujiwara et al., 2013).More recent studies have utilized mesenchymal stem cells
and shown CNS trafficking (Danielyan et al., 2014) and
neurogenesis (Yan et al., 2014) in APP tg mice. Moreover,
other studies have shown that NSC grafting reduced
hippocampal Tau and reelin accumulation in aged Ts65Dn
Down syndrome mice (Kern et al., 2011) and increased
synaptic density in APP tg mice (Blurton-Jones et al., 2009;
Zhang et al., 2014b). Together, these studies support the
notion that transfer of stem cells is beneficial by promoting
neurogenesis and synaptogenesis of endogenous neuronal
circuitries. In agreement with these studies, we found that
combined NSC and CBL treatment was associated with
endogenous neurogenesis and reduced degeneration of the
hippocampal dentate gyrus in the APP tg mice.
However, it should be noted that while in previous studies
the beneficial effects of stem cell monotherapy were noticed
a few weeks post-transplant in our study the combined use of
NSC with CBL continued to be helpful after a long period of
time. As recently noted, poor viability of transplanted cells
could be an important problem associated with stem cell-
based therapy for PD (Nakaji-Hirabayashi et al., 2013) and
other neurodegenerative disorders. For example, a recent
Figure 7 In vitro effects of CBL on markers of cell survival and neurotrophic factors in NSCs. Mouse cortical NSCs were grown in
coverslips for 0, 4 and 8 days and treated with vehicle or CBL at 5% in media with 1% FBS. (A, C, E) Representative images for NSCs
immunostained with an antibody against BrdU, histochemistry for TUNEL or immunostained with an antibody against MAP2 at day 8.
(B, D, F) Computer aided image number of cells displaying BrdU, TUNEL of MAP2 reactivity at 0, 4 and 8 DIV. * = p b 0.05 between
vehicle- and CBL NSCs by two-tailed, Student T-test. Bar = 10 μm. (G, H) ELISA analysis for BDNF and furin in cell lysates at 8 DIV
following vehicle or CBL treatment. * = p b 0.05 by two-tailed, Student T-test.
64 E. Rockenstein et al.study showed that combining a collagen hydrogel incorporat-
ing an integrin-binding protein complex as a carrier for neural
stem cells improve the viability after transplantation into the
striatum (Nakaji-Hirabayashi et al., 2013). Similarly, it has
been shown that co-transplantation of GDNF-overexpressing
NSCs and fetal neurons ameliorates the motor deficits in a rat
model of PD (Deng et al., 2013). Along these lines, for the
present study we combined the NSC graft with adjuvant
therapy with CBL in an effort to enhance the survival of the
transplanted cells. The mechanisms through which CBL might
enhance the survival of the grafted cells are not completely
clear. One possibility is that CBL might reduce the accumula-
tion of toxic Aβ species that can potentially damage the
grafted NSC. In agreement with this we showed lower levels of
Aβload following 6 and 9 months of CBL treatment. Moreover
previous studies have shown that CBL reduces Aβ production
by reducing maturation of APP mediated by CDK5 and GSK3β
activation (Rockenstein et al., 2006). In addition, we showed
that CBL increased furin levels, which in turn resulted in
increased processing of pro-BDNF into BDNF in the grafted
cells. This is consistent with previous studies showing that CBL
might increase levels of NGF perhaps involving the processing
of pro-NGF to its mature form (Ubhi et al., 2013). The
observed increase in furin levels in CBL-treated APP tg mice is
consistent with this hypothesis.
Like pro-NGF (Fahnestock et al., 2001; Peng et al., 2004)
pro-BNDF is the precursor protein of BDNF, which is abundant
in the hippocampus (Barker, 2009; Bekinschtein et al., 2014;Lessmann and Brigadski, 2009; West et al., 2014). Pro-BDNF
undergoes cleavage by a family of mammalian processing
enzymes, including furin (Chen et al., 2015; Fugere and Day,
2005; Seidah and Chretien, 1999). To date there are nine
known convertases (Fugere and Day, 2005; Seidah and
Chretien, 1999) with furin being the most documented.
Moreover, the furin recognition site has been reported to be
essential for the proper processing of pro-BDNF to the mature
form of BDNF (Lim et al., 2007). Previous studies showed that
NSCs are capable of producing BDNF that in turn can protect
neighboring host cells (Blurton-Jones et al., 2009; Zhang
et al., 2014b). The neuropathological analysis showed that
CBL reduced TUNEL and activated caspase-3 in the grafted
NSCs, but had no effect of PCNA or Ki-67 at the later time
points, supporting the notion of a trophic factor mediated
anti-apoptotic effect. However, it is possible that other
mechanisms might be at play, including a limited proliferative
effect soon after transplantation.
In summary, the results of the present study suggest that
CBL is capable of protecting the grafted NSC in an APP tg
mouse model and as such be a potential adjuvant therapy
when combined with cell based therapy.
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